罗氟司特在重度慢阻肺中应答决定因素的汇总分析
该预设汇总分析纳入REACT和RE2SPOND两项随机双盲安慰剂对照研究,共4287例重度慢阻肺患者,评估罗氟司特减少急性加重的作用。结果显示罗氟司特显著降低中重度急性加重12.3%和重度急性加重16.1%,在既往因急性加重住院、频繁急性加重或血嗜酸性粒细胞≥150 cells/μl的患者中获益更明显。
要点
- 罗氟司特降低重度慢阻肺患者中重度急性加重12.3%,重度急性加重16.1%。
- 既往因急性加重住院者获益最大,中重度急性加重风险比0.74。
- 基线血嗜酸性粒细胞≥150 cells/μl者中重度急性加重风险比0.81。
核心结论
- 罗氟司特可减少重度慢阻肺患者急性加重,在既往住院、频繁急性加重或血嗜酸性粒细胞≥150 cells/μl者中获益更显著。
研究设计与样本
- REACT和RE2SPOND两项多中心随机双盲安慰剂对照研究的预设汇总分析,意向治疗人群n=4287。
主要发现
- 总体人群中,罗氟司特较安慰剂降低中重度急性加重12.3%(率比0.88,95%CI 0.80-0.97,P=0.0086),降低重度急性加重16.1%(0.84,0.71-0.99,P=0.0409)。
- 既往因急性加重住院者中重度急性加重率比0.74(0.63-0.88,P=0.0005);既往一年急性加重>2次者率比0.79(0.65-0.96,P=0.0160)。
- 基线血嗜酸性粒细胞≥150 cells/μl者中重度急性加重率比0.81(0.71-0.93,P=0.0020),≥150至<300 cells/μl者0.84(0.71-0.98,P=0.0282),≥300 cells/μl者0.77(0.61-0.97,P=0.0264)。
- 既往住院且血嗜酸性粒细胞≥150 cells/μl者中重度急性加重降低34.5%(0.65,0.52-0.82,P=0.0003),≥300 cells/μl者降低42.7%(0.57,0.37-0.88,P=0.0111)。
临床怎么用
- 对既往因急性加重住院、频繁急性加重或血嗜酸性粒细胞≥150 cells/μl的重度慢阻肺患者,可考虑罗氟司特以减少急性加重。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of exacerbations. Further characterization of patients most likely to benefit is warranted. OBJECTIVES: Define characteristics that most robustly identify patients who derive greatest exacerbation risk reduction with roflumilast. METHODS: Predefined, pooled analyses of REACT (Roflumilast in the Prevention of COPD Exacerbations While Taking Appropriate Combination Treatment; NCT01329029) and RE2SPOND (Roflumilast Effect on Exacerbations in Patients on Dual [LABA/ICS] Therapy; NCT01443845) multicenter, randomized, double-blind, placebo-controlled studies. The primary endpoint was rate of moderate or severe exacerbations per patient per year. MEASUREMENTS AND MAIN RESULTS: In the overall intention-to-treat population (n = 4,287), roflumilast reduced moderate or severe exacerbations by 12.3% (rate ratio, 0.88, 95% confidence interval, 0.80-0.97; P = 0.0086) and severe exacerbations by 16.1% (0.84; 0.71-0.99; P = 0.0409) versus placebo. The reduction in moderate or severe exacerbations with roflumilast was most pronounced in patients who had been hospitalized for an exacerbation in the prior year (0.74; 0.63-0.88; P = 0.0005); had more than two exacerbations in the prior year (0.79; 0.65-0.96; P = 0.0160); or had baseline eosinophils ≥150 cells/μl (0.81; 0.71-0.93; P = 0.0020), ≥150 to <300 cells/μl (0.84; 0.71-0.98; P = 0.0282), or ≥300 cells/μl (0.77; 0.61-0.97; P = 0.0264). Similar subgroup results were noted for severe exacerbations. In patients with prior hospitalization and higher baseline blood eosinophil concentrations, roflumilast reduced moderate or severe exacerbations by 34.5% at ≥150 cells/μl (0.65; 0.52-0.82; P = 0.0003) and 42.7% at ≥300 cells/μl (0.57; 0.37-0.88; P = 0.0111) versus placebo. CONCLUSIONS: This prespecified, pooled analysis confirms the benefit of roflumilast in decreasing exacerbations in patients with prior hospitalization for exacerbation, greater exacerbation frequency, and higher (≥150 cells/μl, ≥150 to <300 cells/μl, or ≥300 cells/μl) baseline blood eosinophil count.
引用
- Martinez FJ, Rabe KF, Calverley PMA, et al. Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. Am J Respir Crit Care Med. 2018. PMID: 29763572. doi:10.1164/rccm.201712-2493OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。